T Cell News and Research

Latest T Cell News and Research

Caring for wife with breast cancer can affect men's health

Caring for a wife with breast cancer can have a measurable negative effect on men's health, even years after the cancer diagnosis and completion of treatment, according to recent research.

17 Apr 2012

ImmunoGen commences IMGN529 Phase I trial in NHL

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.

17 Apr 2012

Coronary stents do not increase risk of heart attack, death in people with metal allergies

Cardiologists have long grappled with how to best manage patients with coronary artery disease who report skin hypersensitivity to nickel or other metal components found in stents -- small tubes placed in narrowed or weakened arteries to help improve blood flow to the heart. But new Mayo Clinic research, published in the April 16, 2012, issue of Circulation: Cardiovascular Interventions, may help allay these concerns.

17 Apr 2012

New study describes therapeutic approach to halt cancer progression

A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.

17 Apr 2012

Study finds lower cytokine levels in the plasma of children with autism

A University of Kansas Medical Center study found significantly lower levels of several cytokines, the immune system's messengers and regulators, in the plasma of children with autism disorder (AD) compared to that of unrelated healthy siblings from other families who had members with autism spectrum disorders.

17 Apr 2012

Study: Kidney cancer growth depends on autophagy

New research at the University of Cincinnati (UC) suggests that kidney cancer growth depends on autophagy, a complex process that can provide cells with nutrients from intracellular sources. Researchers say in certain circumstances autophagy can protect tumor cells from chemotherapy, allowing them to survive for long periods of time in a hidden, dormant, metastatic state.

17 Apr 2012

International Microbicides Conference to discuss state of HIV prevention research

Researchers, activists and funders are meeting this week in Sydney to discuss the state of HIV prevention research. The biennial International Microbicides Conference, which was opened on Sunday evening by the Honorable Tanya Plibersek MP, Australian Minster of Health, is taking place amid renewed optimism about development and delivery of new HIV prevention options with the potential for ending the AIDS epidemic, including anti-retroviral based microbicides and pre-exposure prophylaxis.

17 Apr 2012

UCSF scientists assemble high-value genetic resource to help researchers

One of the ultimate ways of understanding what impact any particular gene has in human health or disease is to disrupt it-knocking it down or wiping it out in a worm, fly or mouse and gauging what happens next. Now scientists at the University of California, San Francisco (UCSF) Diabetes Center and the Gladstone Institute for Cardiovascular Disease have assembled a large publicly available resource to help researchers determine the importance of genes in mice and better gauge what roles they might play in disease.

17 Apr 2012

MTR can prevent cell death in patients with TBI

Wake Forest Baptist Medical Center researchers seeking a successful treatment for traumatic brain injury have found that the size and extent of damaged tissue can be reduced by using a new device to prevent cell death.

17 Apr 2012

Nurr1 gene plays a fundamental role in neuron survival

Researchers at the Institute of Neurosciences at Universitat Aut-noma de Barcelona (INc-UAB) identified the fundamental role played by the Nurr1 gene in neuron survival associated with synaptic activity. The discovery, published in the Journal of Biological Chemistry, allows scientists to study a new target that could help to understand the relationship between alterations in neural connections, which are known to cause early cognitive deficit, and the neurodegeneration characteristic of Alzheimer's disease.

17 Apr 2012

Lack of mLin41 gene regulator can cause neural tube defects

Researchers at the University of Colorado School of Medicine have found that lack of a specific gene interrupts neural tube closure, a condition that can cause death or paralysis.

17 Apr 2012

Air pollution can contribute to obesity in children

Overall, 17% of children in the United States are obese, and in inner-city neighborhoods, the prevalence is as high as 25%. While poor diets and physical inactivity are the main culprits, there is new evidence that air pollution can play a role.

17 Apr 2012

Hydrophilic carbon cluster HADES can selectively kill brain cancer cells

Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.

17 Apr 2012

Two related enzymes play a key role in development of T-ALL

Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes - phosphoinositide-3 kinase (PI3K) gamma and delta - play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat.

17 Apr 2012

UTHealth researcher studies novel cell therapy to prevent GVHD

A researcher at The University of Texas Health Science Center at Houston (UTHealth) is studying a novel cell therapy that could help avoid autoimmune problems after stem cell transplantation, as well as potentially treat other autoimmune diseases.

17 Apr 2012

States roundup: Calif. mental health system grapples with controversy, shortage; Texas issues new stem cell rules

In 2006, the U.S. Department of Justice sued the state, alleging that it was violating patients' rights by heavily drugging and improperly restraining them and failing to provide appropriate treatment. The state settled, agreeing to an extensive court-supervised improvement plan at four hospitals with more than 4,000 patients. But a Times investigation found that the plan has failed to achieve the Justice Department's main objective: to raise the level of care so patients could control their violent tendencies and would not be institutionalized any longer than necessary.

17 Apr 2012

Study pinpoints compounds that repress cancer gene’s activity

A research team pursuing one of the most commonly altered genes in cancer has laid a critical foundation for understanding this gene that could point the way toward developing drugs against it. A recent study of cancer genetics pointed to the gene MCL1, which encodes a protein that helps keep cells alive

17 Apr 2012

Osprey Medical closes IPO raising of A$20 million

Osprey Medical Inc, has today announced that its Initial Public Offer (IPO) raising of A$20 million has closed. Osprey Medical’s Offer was well supported by institutional and retail investors in Australia, including founding investors CM Capital and Brandon Capital. The Initial Public Offer was underwritten by Shaw Corporate Finance.

17 Apr 2012

Novasep’s outstanding results in scale-up and biomanufacturing of Apo-A1 acknowledged by Cerenis at BioProcess International Conference

Novasep, a provider of purification-based manufacturing solutions for lifescience molecules, has announced that Cerenis Therapeutics has been invited by BioProcess International to present its major project CER – 001 ApoA1 - HDL mimetic drug candidate, and describe how Novasep played a critical role in the project by successfully achieving the transfer and scale up of Apo-A1 production.

16 Apr 2012

Merck, Endocyte enter vintafolide development and commercialization agreement

Merck, known as MSD outside the United States and Canada, and Endocyte Inc., today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145).

16 Apr 2012